Oestrogen and nerve growth factor – neuroprotection and repair in Alzheimer’s disease

Bibliography

• ALLEN SJ, MACGOWAN SH, TREANOR JJ, FEENEY R, WILCOCK GK, DAWBARN D: Normal beta-NGF content in Alzheimer's disease cerebral cortex and hippocampi. NeuroscL Lett. (1991) 131:135–139.
   PubMed Web of Science ®Google Scholar
• BARON J,HOLZMAN GB, SCHULKIN J: Attitudes of obstetricians and gynecologists toward hormone replacement therapy. Med. Decis. Making (1998) 18:406–411.
   PubMed Web of Science ®Google Scholar
• ••Excellent manuscript on attitudes concerning hormonereplacement.
   Google Scholar
• BEHL C, DAVIS J, COLE G, SCHUBERT D. Vitamin E protects nerve cells from amyloid beta protein toxicity. Biochem. Biophys. Res. Commun. (1992) 186:944–990.
   PubMed Web of Science ®Google Scholar
• BIRGE S: Is there a role for estrogen treatment therapy in the prevention and treatment of dementia? JAGS (1996) 44:865–870.
   PubMed Web of Science ®Google Scholar
• ••Review regarding both clinical and basic science results withoestrogen treatment.
   Google Scholar
• BUSH TL, WHITEMAN MK: Hormone replacement therapy and risk of breast cancer. JAMA (1999) 281:2140–2141.
   PubMed Web of Science ®Google Scholar
• BACKMAN C, ROSE GM, HOFFER BJ et al.: Systemic administration of a nerve growth factor conjugate reverses age-related cognitive dysfunction and prevents cholinergic neuron atrophy. J. Neurosci. (1996) 16:5437–5442.
   PubMed Web of Science ®Google Scholar
• CALD WELL BM: An evaluation of psychological effects of sex hormone administration in aged women. J. Gerontol. (1954) 9:168–174.
   PubMedGoogle Scholar
• •The first placebo-controlled clinical study with oestrogen and memory.
   Google Scholar
• CHANG D, KWAN J, TIMIRAS PS: Estrogens influence growth, maturation and amyloid 6-peptide production in neuroblastoma cells and in a 0-APP transfected kidney 293 cell line. Adv. Exp. Med. Biol. (1997) 23:261–271.
   Google Scholar
• CHARLES V, MUFSON EJ, FRIDEN PM, BARTUS RT, KORDOWER JH: Atrophy of cholinergic basal forebrain neurons following excitotoxic cortical lesions is reversed by intravenous administration of an NGF conjugate. Brain Res. (1996) 728:193–203.
   PubMed Web of Science ®Google Scholar
• COOPER JD, LINDHOLM D, SOFRONIEW MV: Reduced transport of (1250 nerve growth factor by cholinergic neurons and down-regulated TrkA expression in the medial septum of aged rats. Neuroscience (1994) 62:625–629.
   PubMed Web of Science ®Google Scholar
• CUMMINGS JL, VINTERS HV, COLE GM, KHACHATURIANZS: Alzheimer's disease: Etiologies, pathophysiology, cognitive reserve, treatment opportunities. Neurology (1998) 51 (Suppl.):S2–517.
   Google Scholar
• •Review that summarises the clinical and pathological aspects of Alzheimer's disease.
   Google Scholar
• DAVISSON MT, SCHMIDT C, AKESON EC: Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome. Prog. Clin. Biol. Res. (1990) 360:263–280.
   PubMedGoogle Scholar
• EBADI M, BASHIR RM, HEIDRICK ML et al.: Neurotro-phins and their receptors in nerve injury and repair. Neurochem. Int. (1997) 30:347–74.
   PubMed Web of Science ®Google Scholar
• EMMETT CJ, ASWANI SP, STEWART GR, FAIRCHILD D, JOHNSON RM: Dose-response comparison of recombi-nant human nerve growth factor and recombinant human basic fibroblast growth factor in the fimbria fornix model of acute cholinergic degeneration. Brain Res. (1995) 673:199–207.
   PubMed Web of Science ®Google Scholar
• FADER AJ, JOHNSON PEM, DOHANICH GP: Estrogen improves working but not reference memory and prevents amnestic effects of scopolamine on a radial arm maze. Pharm. Biochem. Behav. (1999) 62:711–717.
   PubMed Web of Science ®Google Scholar
• FARLOW MR: Ethiology and pathogenesis of Alzheimer's disease. Am. J. Health-Syst. Pharm. (1998) 55 (Suppl. 2):S5–S10.
   Google Scholar
• FISHER W, WICTORIN K, BJORKLUND A, WILLIAMS LR,VARON S, GAGE FH: Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by NGF. Nature (1987) 329:53–61.
   Google Scholar
• FRIDEN PM, WALUS LR, WATSON P et al.: NGF-anti-transferrin receptor antibody conjugate crosses the blood-brain barrier and enhances survival of medial septal nucleus neurons. Science (1993) 259:373–377.
   PubMed Web of Science ®Google Scholar
• GIBBS RB: Impairment of basal forebrain cholinergic neurons associated with aging and long-term loss of ovarian function. Exp. Neurol. (1998) 151:289–302.
   PubMed Web of Science ®Google Scholar
• GNAHN H, HEFTI F, HEUMANN R, SCHWAB ME, THOENEN H: NGF-mediated increase of choline acetyl-transferase (ChAT) in the neonatal rat forebrain: evidence for a physiological role of NGF in the brain? Dev. Brain Res. (1983) 9:45–52.
   Web of Science ®Google Scholar
• GRACY RW, TALENT JM, KONG Y, CONRAD CC: Reactiveoxygen species: the unavoidable environmental insult? Mutation Res. (1999) 428:17–22.
   Google Scholar
• GRANHOLM A-CH, ALBECK D, BACKMAN C: A non-invasive system for delivering neural growth factors across the blood-brain barrier: a review. In: Reviews in the Neurosciences (1998) 9:31–55.
   PubMed Web of Science ®Google Scholar
• •Review that describes a transferrin-mediated non-invasive drug delivery system across the intact blood-brain barrier.
   Google Scholar
• GRANHOLM A-C, SANDERS L.A, CRNIC LS: Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down's syndrome. Exp. Neurol. (2000) (In Press).
   Google Scholar
• •This manuscript describes a mouse model with cholinergic degeneration and memory impairment, that can be used to study drug interactions between APP, oestrogen and NGF.
   Google Scholar
• HARING R, FISHER A, MARCIANO D et al.: Mitogen- activated protein kinase-dependent pathways and protein kinase C dependent pathways link the ml muscarinic receptor to beta-amyloid precursor protein secretion. J. Neurochem. (1998) 71:2094–2103.
   PubMed Web of Science ®Google Scholar
• HEFTI F, WILL B: Nerve growth factor is a neurotrophic factor for forebrain cholinergic neurons: implications for Alzheimer's disease? J. Neural Transm. (1987) 24 (Suppl.):309–315.
   Google Scholar
• HONJO H et al: Estrogen as a growth factor to central nervous cells. J. Steroid Biochem. Mol. Biol. (1992) 41:633–635.
   PubMed Web of Science ®Google Scholar
• HSIAO K, CHAPMAN P, NILSEN S et al: Correlative memory deficits, Ab elevation, amyloid plaques in transgenic mice. Science (1996) 274:99–102.
   PubMed Web of Science ®Google Scholar
• INESTROSA NC, MARZOLO MP, BONNEFONT AB: Cellular and molecular basis of estrogen's neuropro-tection. Potential relevance for Alzheimer's disease. Molec. Neurobiol (1998) 17:73–86.
   Google Scholar
• ••A review that covers the basic mechanisms for estrogen'sneuroprotective effects.
   Google Scholar
• JAFFE AB, TORAND-ALLERAND CD, GREENGARD P, GANDY SE: Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein. J. Biol. Chem. (1994) 269:13065–13068.
   PubMed Web of Science ®Google Scholar
• KOLIATSOS VE, CLATTERBUCK RE, NAUTA HJW et al: Human nerve growth factor prevents degeneration of basal forebrain cholinergic neurons in primates. Ann. Neurol (1991) 30:831–840.
   PubMed Web of Science ®Google Scholar
• LAHIRI D.K, FARLOW M.R, SAMBAMURTI K: The secretion of amyloid beta-peptides is inhibited in tacrine-treated human neuroblastoma cells. Brain Res. Mol Brain Res. (1998) 62:131–40.
   PubMedGoogle Scholar
• LE BROCQUE D, HENRY A, CAPPA I et al.: Processing ofthe Alzheimer's disease amyloid precursor protein in Pichia pastoris: immunodetection of alpha- beta-, and gamma-secretase products. Biochemistry (1998) 37:14958–14965.
   PubMed Web of Science ®Google Scholar
• MARKOWSKA AL, KOLIATSOS VE, BRECKLER SJ, PRICEDL, OLTON DS: Human nerve growth factor improves spatial memory in aged but not in young rats. J. Neurosci. (1994) 14:4815–4824.
   PubMed Web of Science ®Google Scholar
• MCEWEN BS, ALVES SE, BULLOCH K, WEILAND NG: Ovarian steroids and the brain: Implications for cognition and aging. Neurology (1997) 48\(Suppl. 7):S8–515.
   Google Scholar
• MILWARD EA, PAPADOPOULOS R, FULLER SJ et aLThe amyloid protein precursor of Alzheimer's disease is a mediator of the effects of nerve growth factor on neurite outgrowth. Neuron (1992) 9:129–137.
   PubMed Web of Science ®Google Scholar
• MITLAK BH, COHEN FJ: Selective estrogen receptor modulators: a look ahead. Drugs (1999) 57:653–663.
   PubMed Web of Science ®Google Scholar
• MUFSON EJ, CONNER JM, KORDOWER JH: Nerve growth factor in Alzheimer's disease: defective retrograde transport to nucleus basalis. Neuroreport (1995) 6:1063–1066.
   PubMed Web of Science ®Google Scholar
• •This manuscript describes the novel theory of Alzheimer's disease, that NGF transport may be the causative factor.
   Google Scholar
• MUFSON EJ, LI JM, SOBREVIELA T, KORDOWER JH: Decreased trkA gene expression within basal forebrain neurons in Alzheimer's disease. Neuroreport (1996) 8:25–29.
   PubMed Web of Science ®Google Scholar
• MUFSON EJ, LAVINE N, JAFFAR S, KORDOWER JH, QUIRION R, SARAGOVI HU: Reduction in p140-TrkA receptor protein within the nucleus basalis and cortex in Alzheimer's disease. Exp. Neurol (1997) 146:91–103.
   PubMed Web of Science ®Google Scholar
• MURASE K, NABESHIMA T, ROBITAILLE Y, QUIRION R,OGAWA M, HAYASHI K: NGF level is not decreased in the serum, brain-spinal fluid, hippocampus, or parietal cortex of individuals with Alzheimer's disease. Biochem. Biophys. Res. Comm. (1993) 193:198–203.
   PubMed Web of Science ®Google Scholar
• OLSON L: NGF and the treatment of Alzheimer's disease. Exp. Neurol (1993) 124:5–15.
   PubMed Web of Science ®Google Scholar
• ••The first manuscript describing clinical trials with NGFinfusion into Alzheimer's patients.
   Google Scholar
• PAPPOLLA MA, CHYAN YJ, POEGGLER B et al.: Alzheimer beta protein mediated oxygen damage of mitochon-drial DNA: prevention by melatonin. J. Pineal Res. (1999) 27:226–229.
   PubMed Web of Science ®Google Scholar
• PERRY EK, TOMLINSON BE, BLESSED G, PERRY RH, CROSS AJ, CROW TJ: Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br. Med. J. (1978) 2:1457–1459.
   PubMed Web of Science ®Google Scholar
• PRICE DL: New order from neurological disorders.Nature (1999) 399(Suppl.):A3–A5.
   Google Scholar
• RAMASSAMY C, AVERILL D, BEFFERT U et al.: Oxidativedamage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipo-protein E genotype. Free Rad. Biol. Med. (1999) 27:544–553.
   PubMed Web of Science ®Google Scholar
• REEVES RH, IRVING NG, MORAN TH: A mouse model for Down syndrome exhibits learning and behavioral deficits. Nature Gen. (1995) 11:177–184.
   PubMed Web of Science ®Google Scholar
• RISSANEN A, PUOLIVALI J, VAN GROEN T, RIEKKINEN P: In mice tonic estrogen replacement therapy improves non-spatial and spatial memory in a water maze task. NeuroReport (1999) 10:1369–1372.
   PubMed Web of Science ®Google Scholar
• ROSSNER S, UEBERHAM U, SCHLIEBS R, PEREZ-POLO JR, BIGL V: Neurotrophin binding to the p75 neurotro-phin receptor necessary but not sufficient to mediate NGF-effects on APP secretion in PC12 cells. J. Neural Transm. (1998) 54 (Suppl.):279–285.
   Google Scholar
• SALEHI A, VERHAAGEN J, DIJKHUISEN PA, SWAAB DF: Co-localization of high-affinity neurotrophin receptors in nucleus basalis of Meynert neurons and their differential reduction in Alzheimer's disease. Neuroscience (1996) 75:373–387.
   PubMed Web of Science ®Google Scholar
• SCHENK D, BARBOUR R, DUNN W et al. Immunizationwith amyloid-6 attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature (1999) 400:173–177.
   PubMed Web of Science ®Google Scholar
• SCHNEIDER LS, FARLOW MK, HENDERSON VW, POGODAL JM: Estrogen replacement therapy may enhance response to tacrine in women with Alzheimer's disease. Neurology (1995) 45(Suppl.):A288.
   Google Scholar
• SCOTT SA, MUFSON EJ, WEINGARTNER JA, SKAU KA, CRUTCHER KA: Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis. j NeuroscL (1995) 15:6213–6221.
   PubMed Web of Science ®Google Scholar
• SEIGER A, NORDBERG A, VON HOLST H, et al.: Intracra-nial infusion of purified nerve growth factor to an Alzheimer patient: the first attempt of a possible future treatment strategy. Behav. Brain Res. (1993) 57:255–261.
   Google Scholar
• SEILER M, SCHWAB ME: Specific retrograde transport of nerve growth factor receptor (NGF) from neocortex to nucleus basalis in the rat. Brain Res. (1984) 300:33–39.
   PubMed Web of Science ®Google Scholar
• SELKOE DJ: Translating cell biology into therapeutic advances in Alzheimer's disease. Nature (1999) 399 (Suppl.):A23–A31.
   Google Scholar
• ••Excellent and insightful review regarding the APP/amyloidcascade.
   Google Scholar
• SHI J, PANICKAR KS, YANG SH, RABBANI 0, DAY AL, SIMPKINS JVV: Estrogen atteunuates over-expression of beta-amyloid precursor protein messenger RNA in an animal model of focal ischemia. Brain Res. (1998) 810:87–92.
   PubMed Web of Science ®Google Scholar
• SIMPKINS JW et al.: Role of estrogen replacement therapy in memory enhancement and the prevention of neuronal loss associated with Alzheimer's disease. Am. J. Med. (1997) 103:19S–24S.
   Google Scholar
• SMITH DE, ROBERTS J, GAGE FH, TUSZYNSKI MH: Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy. Proc. Natl. Acad. ScL USA (1999) 96:10893–10898.
   PubMed Web of Science ®Google Scholar
• SOURANDER L, RAJALA T, RAIHA I, MAKINEN J, ERKKOLA R, HELENIUS H: Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmeno-pausal women on oestrogen replacement therapy (ERT). Lancet (1998) 352:1965–1969.
   PubMed Web of Science ®Google Scholar
• SRAMEK JJ, CUTLER NR: Recent developments in thedrug treatment of Alzheimer's disease. Drugs Aging (1999) 14:359–373.
   PubMed Web of Science ®Google Scholar
• •This review focuses on drug development in Alzheimer's disease.
   Google Scholar
• SRIVASTAVA RA, BHASIN N, SRI VASTAVA N: Apolipoprotein E gene expression in various tissues of mouse and regulation by estrogen. Biochem. Mol Biol. InL (1996) 38:91–101.
   PubMedGoogle Scholar
• TORAND-ALLERAND CD: The estrogen/neurotrophin connection during neural development: is colocaliza-tion of estrogen receptors with the neurotrophins and their receptors biologically relevant? Dev. Neurosci. (1996) 18:36–48.
   Web of Science ®Google Scholar
• WATSON MA, MILBRANDT J: The NGFI-6 gene, a transcriptionally inducible member of the steroid receptor gene superfamily: Genomic structure and expression in rat brain after seizure induction. Ma Cell Biol. (1989) 9:4213–4219.
   Web of Science ®Google Scholar
• WALLACE WC, AKAR CA, LYONS WE: Amyloid precursor protein potentiates the neurotrophic activity of NGF. Brain Res. Mol Brain Res. (1997) 52:201–212.
   PubMedGoogle Scholar
• WINDISCH M, GSCHANES A, HUTTER-PAIER B: Neurotrophic activities and therapeutic experience with a brain derived peptide preparation. J. Neural Transm. (1998) 53:289–298.
   Google Scholar
• WISE MR, STEWART DE, LIU P, ABRAHAMSON BL: Use of hormone replacement therapy among cardiac patients at a Canadian academic centre. CMAJ (1999) 161:33–36.
   PubMed Web of Science ®Google Scholar
• WOLFE MS, DE LOS ANGELES J, MILLER DD, XIA W, SELKOE DJ: Are presenilins intramembrane-cleaving proteases? Implications for the molecular mechanism of Alzheimer's disease. Biochemistry (1999) 38:11223–11230.
   PubMed Web of Science ®Google Scholar